tafasitamab   Click here for help

GtoPdb Ligand ID: 11131

Synonyms: Minjuvi® | Monjuvi® | MOR-208 | MOR00208 | MOR208 | tafasitamab-cxix | Xmab5574
Approved drug Immunopharmacology Ligand
tafasitamab is an approved drug (FDA (2020), EMA (2021))
Compound class: Antibody
Comment: Tafasitamab (MOR208, formerly Xmab®5574) is a humanized Fc-engineered monoclonal antibody directed against CD19 that was developed by MorphoSys [4]. XmAb® antibodies are designed with modifications in their Fc domain (S239D/I332E mutations) that increase binding to Fcγ receptors on immune cells. This optimises the antibody's Fc-mediated effector function (i.e. antibody-dependent cell-mediated cytotoxicity, ADCC) [1,5]. At the beginning ot 2020, MorphoSys and Incyte Corporation entered into a collaboration and license agreement for the global development and commercialization of tafasitamab (MOR208).
Classification Click here for help
Compound class Antibody
Approved drug? Yes (FDA (2020), EMA (2021))
International Nonproprietary Names Click here for help
INN number INN
10835 tafasitamab
Synonyms Click here for help
Minjuvi® | Monjuvi® | MOR-208 | MOR00208 | MOR208 | tafasitamab-cxix | Xmab5574
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 522
Other databases
GtoPdb PubChem SID 434122191
Search PubMed clinical trials tafasitamab
Search PubMed titles tafasitamab
Search PubMed titles/abstracts tafasitamab